The great thing about technology is that it is always getting better. Advancements that were once revolutionary become commonplace, and new developments further increase performance, convenience, and accuracy. Such is the case with the Abbott FreeStyle Libre, which dramatically improved the lives of people with diabetes by facilitating continuous glucose monitoring (CGM).
Abbott introduced the popular little white sensor worn on the arm years ago along with a handheld scanner that users need to swipe over the sensor to get readings. Now, Abbott is on the cusp of making that swipe a thing of the past with a more automated and easier way to get blood glucose readings.
In September 2020, Abbott Diabetes obtained international approval of its tiny FreeStyle Libre 3 version outside the United States, with plans to bring it to the U.S. in the near future.
No More Scanning Required
Libre 3 has several advantages over existing models, the biggest being the elimination of the need to scan the sensor. For many people, that continued need to scan before obtaining a result meant the Libre 2 still didn’t provide the ideal level of protection for high and low glucose levels. This is particularly important overnight, when hypoglycemia can be even more dangerous since users are asleep and not actively monitoring or experiencing symptoms.
Additionally, the new sensor is much smaller and thinner than previous versions, with about the same thickness as two pennies.
The new device generates a real-time blood glucose reading every minute and displays the result on the compatible Android or iPhone mobile app. This continuous data stream comes with optional real-time alerts for high and low blood sugar levels, along with instant glucose results. As with earlier FreeStyle models, the Libre 3 still must warm up for one hour before providing data.
Closed-Loop Technology On The Way
Abbott has signed multiple development agreements with partners that will allow its Libre monitor to work with future closed-loop technology, or Automated Insulin Delivery (AID) systems.
In June 2020, the FDA granted the Libre 2 a special iCGM designation, meaning it has the potential to work with other pieces of diabetes technology. The new Libre 3 will likely receive the full iCGM approval shortly after its launch in the U.S.
Learn More About How CGM Can Change The Way You Manage Diabetes
CGM is a tested, customizable transceiver device that helps those with diabetes stay in control of their condition and their life. As technology like the Libre 3 continues to develop, CGM will become even more easy-to-use and provide the information users need when they need it with minimal effort and inconvenience.
Whether you’ve been living with diabetes for years or if you’ve recently received a diagnosis, CGM may be an excellent glucose monitoring solution. Contact us today to see if you qualify for CGM and access our guide to continuous glucose monitoring.